123.66
price up icon0.51%   0.63
after-market アフターアワーズ: 123.66
loading
前日終値:
$123.03
開ける:
$123.2
24時間の取引高:
832.05K
Relative Volume:
0.56
時価総額:
$12.24B
収益:
$2.41B
当期純損益:
$305.80M
株価収益率:
41.92
EPS:
2.95
ネットキャッシュフロー:
$492.20M
1週間 パフォーマンス:
+3.81%
1か月 パフォーマンス:
+15.31%
6か月 パフォーマンス:
-2.44%
1年 パフォーマンス:
-8.14%
1日の値動き範囲:
Value
$122.25
$125.63
1週間の範囲:
Value
$117.59
$125.63
52週間の値動き範囲:
Value
$84.23
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1177)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
1,800
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

NBIX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
123.66 11.79B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.33 49.79B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
167.14 72.11B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.76 4.24M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.80 45.01B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.53 19.43B 16.54B -1.64B 749.00M -1.45

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
06:23 AM

Neurocrine Biosciences director sells shares worth $1.16 million - Investing.com

06:23 AM
pulisher
01:36 AM

Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophr - GuruFocus

01:36 AM
pulisher
11:13 AM

Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff - Endpoints News

11:13 AM
pulisher
12:06 PM

Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched - Yahoo

12:06 PM
pulisher
May 28, 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - GlobeNewswire Inc.

May 28, 2025
pulisher
May 28, 2025

Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophrenia Treatment | NBIX Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results - Investing.com

May 28, 2025
pulisher
May 28, 2025

Neurocrine reports positive Phase 2 schizophrenia study results By Investing.com - Investing.com UK

May 28, 2025
pulisher
May 28, 2025

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - PR Newswire

May 28, 2025
pulisher
May 25, 2025

Neurocrine Biosciences’ SWOT analysis: stock’s resilience amid market challenges - Investing.com Australia

May 25, 2025
pulisher
May 24, 2025

How to Take Advantage of moves in (NBIX) - news.stocktradersdaily.com

May 24, 2025
pulisher
May 23, 2025

Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Nasdaq

May 23, 2025
pulisher
May 20, 2025

Neurocrine at RBC Conference: Growth and Strategic Insights - Investing.com

May 20, 2025
pulisher
May 20, 2025

Transcript : Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11 - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourette Syndrome Treatment Market Detailed Analysis - openPR.com

May 20, 2025
pulisher
May 17, 2025

Neurocrine Biosciences (NBIX) Shares Positive Results from Pedia - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Neurocrine reports quality of life gains in tardive dyskinesia study By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Neurocrine Presents Encouraging New Data From Phase 4 Study Of Ingrezza In Tardive Dyskinesia - Nasdaq

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports lasting benefits of CRENESSITY in CAH study By Investing.com - Investing.com India

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences Says Tardive Dyskinesia Treatment Improves Functional, Quality of Life Measures - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports quality of life gains in tardive dyskinesia study - Investing.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports progress for CAH drug as Voyager partnership shifts - The Pharma Letter

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports lasting benefits of CRENESSITY in CAH study - Investing.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting - PR Newswire

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia - WV News

May 16, 2025
pulisher
May 16, 2025

Clinical Trial Breakthrough: New Data Reveals How INGREZZA Transforms Daily Life for Tardive Dyskinesia Patients - Stock Titan

May 16, 2025
pulisher
May 15, 2025

Neurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

90% Success Rate: CRENESSITY Shows Breakthrough Results in Congenital Adrenal Hyperplasia | NBIX Stock News - Stock Titan

May 15, 2025
pulisher
May 15, 2025

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont) - PR Newswire

May 15, 2025
pulisher
May 14, 2025

Neurocrine (NBIX) Highlights Risks of High Glucocorticoid Doses in CAH Patients | NBIX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia - PR Newswire

May 14, 2025
pulisher
May 14, 2025

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results - Longview News-Journal

May 14, 2025
pulisher
May 14, 2025

New Research Reveals Dangerous Side Effects of High-Dose Steroids in CAH Treatment: What Doctors Need to Know - Stock Titan

May 14, 2025
pulisher
May 13, 2025

15 Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Neurocrine at BofA Conference: Strategic Moves and Market Challenges - Investing.com

May 13, 2025
pulisher
May 13, 2025

Learn to Evaluate (NBIX) using the Charts - news.stocktradersdaily.com

May 13, 2025
pulisher
May 13, 2025

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Neurocrine Biosciences To Present BofA Securities 2025 Health Care Conference; Webcast At 2:20 PM ET - Nasdaq

May 13, 2025
pulisher
May 12, 2025

Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis - HCPLive

May 12, 2025
pulisher
May 12, 2025

Cognitive Impairment Associated with Schizophrenia Pipeline - openPR.com

May 12, 2025
pulisher
May 12, 2025

Cognitive Impairment Associated with Schizophrenia Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Cyclerion Therapeutics, Biogen, Neurocrine - Barchart.com

May 12, 2025
pulisher
May 12, 2025

Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality - Yahoo Finance

May 12, 2025
pulisher
May 11, 2025

Earnings Tell The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) As Its Stock Soars 27% - simplywall.st

May 11, 2025
pulisher
May 10, 2025

Wedbush Lifts Earnings Estimates for Neurocrine Biosciences - Defense World

May 10, 2025
pulisher
May 09, 2025

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com

May 09, 2025
pulisher
May 09, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $160.00 - Defense World

May 09, 2025
pulisher
May 09, 2025

Wedbush Forecasts Lower Earnings for Neurocrine Biosciences - Defense World

May 09, 2025
pulisher
May 09, 2025

Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

May 09, 2025
pulisher
May 08, 2025

Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Neurocrine leans on singer Carnie Wilson for tardive dyskinesia push - Medical Marketing and Media

May 08, 2025

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$14.75
price up icon 1.30%
drug_manufacturers_specialty_generic HCM
$13.86
price up icon 4.76%
$8.83
price up icon 2.79%
$320.37
price up icon 1.50%
$17.53
price down icon 3.42%
大文字化:     |  ボリューム (24 時間):